NCT05565391View on ClinicalTrials.gov

A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma

CompletedOBSERVATIONAL
Enrollment

508

Participants

Timeline

Start Date

October 3, 2022

Primary Completion Date

November 4, 2022

Study Completion Date

November 4, 2022

Conditions
Multiple Myeloma
Interventions
DRUG

Elranatamab

BCMA-CD3 bispecific antibody

DRUG

Standard of care

Standard of care

Trial Locations (1)

10001

Pfizer, New York

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05565391 - A Study to Learn About the Medicine (Called Elranatamab) in People With Relapsed Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter